{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:45:46Z","timestamp":1784133946236,"version":"3.55.0"},"reference-count":27,"publisher":"e-Century Publishing Corporation","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/dagb7277","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T03:59:39Z","timestamp":1717127979000},"page":"2465-2477","source":"Crossref","is-referenced-by-count":5,"title":["Mac-2 binding protein glycosylation isomer at 5 years of antiviral therapy predict hepatocellular carcinoma and mortality beyond year 5 in chronic hepatitis B patients with cirrhosis"],"prefix":"10.62347","volume":"14","author":[{"given":"Chien-Hung","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS and Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016; 10: 1-98.","journal-title":"Hepatol Int"},{"key":"ref1","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67: 370-398."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"NA","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM and Murad MH; American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016; 63: 261-283.","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/hep.23785","article-title":"Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B","volume":"52","author":"Chang","year":"2010","unstructured":"Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S and Kreter B. Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-893.","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/hep.26180","article-title":"Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection","volume":"58","author":"Hosaka","year":"2013","unstructured":"Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M and Kumada H. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58: 98-107.","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1002\/hep.26301","article-title":"Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis","volume":"58","author":"Wong","year":"2013","unstructured":"Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Lai JW, Lo AO, Chan HY and Wong VW. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013; 58: 1537-1547.","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1111\/liv.13253","article-title":"Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients","volume":"36","author":"TH","year":"2016","unstructured":"Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, Wang CC, Su WW, Chen MY, Peng CY, Chien RN, Huang YW, Wang HY, Lin CL, Yang SS, Chen TM, Mo LR, Hsu SJ, Tseng KC, Hsieh TY, Suk FM, Hu CT, Bair MJ, Liang CC, Lei YC, Tseng TC, Chen CL and Kao JH; C-TEAM study group and the Taiwan Liver Diseases Consortium. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int 2016; 36: 1755-1764.","journal-title":"Liver Int"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1093\/jac\/dkt147","article-title":"Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants","volume":"68","author":"Yang","year":"2013","unstructured":"Yang SC, Lee CM, Hu TH, Wang JH, Lu SN, Hung CH, Changchien CS and Chen CH. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants. J Antimicrob Chemother 2013; 68: 2154-2163.","journal-title":"J Antimicrob Chemother"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/hep.29320","article-title":"The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B","volume":"66","author":"GV","year":"2017","unstructured":"Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, Calleja JL, Sypsa V, Goulis J, Manolakopoulos S, Loglio A, Siakavellas S, Keskın O, Gatselis N, Hansen BE, Lehretz M, de la Revilla J, Savvidou S, Kourikou A, Vlachogiannakos I, Galanis K, Yurdaydin C, Berg T, Colombo M, Esteban R, Janssen HLA and Lampertico P. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology 2017; 66: 1444-1453.","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s12072-020-10031-3","article-title":"Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients","volume":"14","author":"Sou","year":"2020","unstructured":"Sou FM, Hu TH, Hung CH, Lai HC, Wang JH, Lu SN, Peng CY and Chen CH. Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients. Hepatol Int 2020; 14: 513-520.","journal-title":"Hepatol Int"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3343\/alm.2021.41.1.16","article-title":"Clinical utility of Mac-2 binding protein glycosylation isomer in chronic liver diseases","volume":"41","author":"Tamaki","year":"2021","unstructured":"Tamaki N, Kurosaki M, Loomba R and Izumi N. Clinical utility of Mac-2 binding protein glycosylation isomer in chronic liver diseases. Ann Lab Med 2021; 41: 16-24.","journal-title":"Ann Lab Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"5063","DOI":"10.3390\/cancers14205063","article-title":"A Mac-2 binding protein glycosylation isomer-based risk model predicts hepatocellular carcinoma in HBV-related cirrhotic patients on antiviral therapy","volume":"14","author":"Chen","year":"2022","unstructured":"Chen CH, Hu TH, Wang JH, Lai HC, Hung CH, Lu SN and Peng CY. A Mac-2 binding protein glycosylation isomer-based risk model predicts hepatocellular carcinoma in HBV-related cirrhotic patients on antiviral therapy. Cancers (Basel) 2022; 14: 5063.","journal-title":"Cancers (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR and Heimbach JK. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018; 68: 723-750.","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, Blonde L, Bray GA, Cohen AJ, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda OP, Garber AJ, Garvey WT, Henry RR, Hirsch IB, Horton ES, Hurley DL, Jellinger PS, Jovanovič L, Lebovitz HE, LeRoith D, Levy P, McGill JB, Mechanick JI, Mestman JH, Moghissi ES, Orzeck EA, Pessah-Pollack R, Rosenblit PD, Vinik AI, Wyne K and Zangeneh F. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract 2015; 21 Suppl 1: 1-87.","DOI":"10.4158\/EP15672.GLSUPPL"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/srep01065","article-title":"A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis","volume":"3","author":"Kuno","year":"2013","unstructured":"Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, Hige S, Sakamoto M, Kage M, Mizokami M and Narimatsu H. A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep 2013; 3: 1065.","journal-title":"Sci Rep"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"92431","DOI":"10.18632\/oncotarget.21369","article-title":"Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir","volume":"8","author":"Chen","year":"2017","unstructured":"Chen CH, Lee CM, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Wang JH, Lee MH and Peng CY. Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir. Oncotarget 2017; 8: 92431-92441.","journal-title":"Oncotarget"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1002\/sim.1742","article-title":"Presentation of multivariate data for clinical use: the Framingham study risk score functions","volume":"23","author":"LM","year":"2004","unstructured":"Sullivan LM, Massaro JM and D’Agostino RB Sr. Presentation of multivariate data for clinical use: the Framingham study risk score functions. Stat Med 2004; 23: 1631-1660.","journal-title":"Stat Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy","volume":"64","author":"Papatheodoridis","year":"2016","unstructured":"Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Mangia G, Gatselis N, Keskin O, Savvidou S, de la Revilla J, Hansen BE, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL and Lampertico P. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol 2016; 64: 800-806.","journal-title":"J Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","article-title":"Time-dependent ROC curves for censored survival data and a diagnostic marker","volume":"56","author":"PJ","year":"2000","unstructured":"Heagerty PJ, Lumley T and Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000; 56: 337-344.","journal-title":"Biometrics"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.jhep.2018.07.018","article-title":"Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy","volume":"69","author":"Kim","year":"2018","unstructured":"Kim JH, Kim YD, Lee M, Jun BG, Kim TS, Suk KT, Kang SH, Kim MY, Cheon GJ, Kim DJ, Baik SK and Choi DH. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy. J Hepatol 2018; 69: 1066-1073.","journal-title":"J Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1111\/liv.13938","article-title":"The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B","volume":"38","author":"Kim","year":"2018","unstructured":"Kim BG, Park NH, Lee SB, Jeon S, Park JH, Jung SW, Jeong ID, Bang SJ and Shin JW. The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B. Liver Int 2018; 38: 2269-2276.","journal-title":"Liver Int"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/hepr.12703","article-title":"Clinical implications of serum Wisteria floribunda agglutinin-positive Mac-2-binding protein in treatment-naive chronic hepatitis B","volume":"47","author":"Ishii","year":"2017","unstructured":"Ishii A, Nishikawa H, Enomoto H, Iwata Y, Kishino K, Shimono Y, Hasegawa K, Nakano C, Takata R, Nishimura T, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Iijima H and Nishiguchi S. Clinical implications of serum Wisteria floribunda agglutinin-positive Mac-2-binding protein in treatment-naive chronic hepatitis B. Hepatol Res 2017; 47: 204-215.","journal-title":"Hepatol Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/hepr.12712","article-title":"Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection","volume":"47","author":"Ichikawa","year":"2017","unstructured":"Ichikawa Y, Joshita S, Umemura T, Shobugawa Y, Usami Y, Shibata S, Yamazaki T, Fujimori N, Komatsu M, Matsumoto A and Tanaka E. Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Hepatol Res 2017; 47: 226-233.","journal-title":"Hepatol Res"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1007\/s00535-017-1386-2","article-title":"Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B","volume":"53","author":"Kawaguchi","year":"2018","unstructured":"Kawaguchi K, Honda M, Ohta H, Terashima T, Shimakami T, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Komura T, Unoura M and Kaneko S. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B. J Gastroenterol 2018; 53: 740-751.","journal-title":"J Gastroenterol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s00535-017-1424-0","article-title":"High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues","volume":"53","author":"Shinkai","year":"2018","unstructured":"Shinkai N, Nojima M, Iio E, Matsunami K, Toyoda H, Murakami S, Inoue T, Ogawa S, Kumada T and Tanaka Y. High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues. J Gastroenterol 2018; 53: 883-889.","journal-title":"J Gastroenterol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jhep.2023.02.022","article-title":"International liver cancer association (ILCA) white paper on hepatocellular carcinoma risk stratification and surveillance","volume":"79","author":"Singal","year":"2023","unstructured":"Singal AG, Sanduzzi-Zamparelli M, Nahon P, Ronot M, Hoshida Y, Rich N, Reig M, Vilgrain V, Marrero J, Llovet JM, Parikh ND and Villanueva A. International liver cancer association (ILCA) white paper on hepatocellular carcinoma risk stratification and surveillance. J Hepatol 2023; 79: 226-239.","journal-title":"J Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/hepr.12473","article-title":"Impact of serum glycosylated Wisteria floribunda agglutinin positive Mac-2 binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis","volume":"45","author":"Hanai","year":"2015","unstructured":"Hanai T, Shiraki M, Ohnishi S, Miyazaki T, Ideta T, Kochi T, Imai K, Suetsugu A, Takai K, Shimizu M and Moriwaki H. Impact of serum glycosylated Wisteria floribunda agglutinin positive Mac-2 binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis. Hepatol Res 2015; 45: 1083-1090.","journal-title":"Hepatol Res"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/5\/ajcr0156700.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:53:38Z","timestamp":1766022818000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/5\/ajcr0156700.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/dagb7277","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}